Neil Miller

Advised PayGroup Limited (PayGroup, the Group), a trusted provider of Multi-Country Payroll and Human Resource Outsourcing Solutions, on its Initial Public Offering (IPO) to raise between $5.5 million and $8.5 million.

Managing initial public offerings (IPO) and ASX Listings for Allomak Limited, EvoGenix Ltd, Mesoblast Limited, Octagonal Resources Limited, Patrys Limited, and TSV Holdings Limited.

Acting on several multiple State company and business mergers/consolidations leading to its IPO and ASX Listing (for example, TSV Holdings Limited and Allomak Limited).

Advising and negotiating overseas equity funding arrangements for Australian listed companies (including drafting documents for capital investment in the United States by local companies, overseas investors subscribing locally and underwritings generally).

Conducting the Scheme of Arrangement of Keycorp Limited by private equity group Archer Capital.

Acting on the US$350 million acquisition of 20% stake in Mesoblast Ltd (and US$1.7 billion strategic alliance/milestone payments) with US Listed Cephalon Inc. (now Teva Pharmaceutical Industries Ltd).

Acting on an ASX Listed company demerger/capital distribution and subsequent listing of the spin off entity in Singapore.

Producing complex public company extraordinary general meeting and annual general meeting documentation and information memoranda.

Documenting share buy backs, capital reductions, rights issues, employee share plans, share purchase plans, convertible notes and bonds, underwriting and other capital raising documents for private and public companies.

Acted in a capital raising for Wattle Health Australia Limited (WHA) of AUD74 million consisting of a non-renounceable retail entitlement offer of AUD33.9 million, a AUD20 million private placement to institutional investors, and a debt facility of AU$20 million.